The effect of rabbit antithymocyte globulin on human mesenchymal stem cells

Marcella Franquesa, Carla Baan, Sander Korevaar, AU Engela, Marieke Rhijn, Willem Weimar, M.G.H. Betjes, JM Grinyo, Martin Hoogduijn

Research output: Contribution to journalArticleAcademicpeer-review


Mesenchymal stem cells (MSCs) possess immunomodulatory properties which are of key interest for their application in autoimmunity and transplantation. In transplantation, administration of MSCs has shown promising results in preclinical models and has recently moved to clinical trials. Therefore, it is important to study the interactions between MSCs and immunosuppressive drugs currently used in transplantation. We aimed to analyze the effect of rabbit antithymocyte globulin (rATG) MSCs. MSCs were obtained from perirenal fat of kidney donors and exposed to ranging doses of rATG (Thymoglobulin (R), Genzyme; 0.5100g/ml). Binding of rATG, effects on viability and susceptibility to be killed by cytotoxic lymphocytes as well as effects on their immunosuppressive potential of MSCs were tested. rATG binds dose-dependently to MSCs. This binding was associated with slightly impaired viability after 48 and 72h when compared with nonexposed MSCs. In contrast to nontreated MSCs, rATG preexposed MSCs were susceptible to be lysed by cytokine-activated CD8+ cytotoxic cells and NKT cells. The capacity of MSCs to suppress the proliferation of anti-CD3/CD28 activated CD4 and CD8 T cells were reduced by the presence of rATG in the culture. rATG reduces the viability and antiproliferative capacity of MSCs in a dose-dependent manner and converts them into targets for CD8 T cells and NKT cell lysis.
Original languageUndefined/Unknown
Pages (from-to)651-658
Number of pages8
JournalTransplant International
Issue number6
Publication statusPublished - 2013

Cite this